Selective biologics for ulcerative colitis and Crohn’s disease – clinical utility of vedolizumab

Abstract: Inflammatory bowel disease (IBD) encompasses a cluster of different disease phenotypes which are broadly classified into ulcerative colitis and Crohn’s disease. Disease pathogenesis is driven by abnormal host immune responses to their resident gut microbiome in genetically susceptible individuals. Clinical disease features and outcomes are heterogeneous and not unexpected as over 163 genetic loci are associated with disease susceptibility, and there are great variability in environmental exposures. Despite this variability, there has been relatively few efficacious therapies for particularly moderate-to-severe IBD. Treatment has been dominated by antitumor necrosis alpha agents with significant success but equally potentially serious adverse events. Therapeutic targeting of leukocyte trafficking has emerged as a viable alternative therapy, with vedolizumab being the lead compound. This review focuses primarily on its biological function as a selective gut immunotherapy, its safety and efficacy, and its emerging role as a mainstream therapy in managing IBD.

Keywords: adhesion molecule antagonist, anti-α4β7 integrin, inflammatory bowel disease, leukocyte trafficking, monoclonal antibody, selective gut immunotherapy, tumor necrosis factor alpha

Introduction

Crohn’s disease (CD) and ulcerative colitis (UC), collectively referred to as inflammatory bowel disease (IBD), are chronic inflammatory conditions of the gastrointestinal (GI) tract resulting from an inappropriate immunological response to trigger(s) in the genetically susceptible host’s environment and microbiome. The inflammation of CD is transmural and discontinuous, affecting any portion of the digestive tract, whereas UC is characterized by superficial colonic inflammation that progresses in a continuous manner proximally from the rectum. Diarrhea, blood in the stool, abdominal cramping and pain, fatigue, weight loss, and malnutrition are hallmark symptoms of IBD, often associated with extra-intestinal manifestations involving the joints, skin, eyes, and liver.

IBD affects more than 233,000 Canadians (equating to one in 150 Canadians), with more than 10,000 new cases diagnosed each year; it is as common as type 1 diabetes and epilepsy, and twice as common as multiple sclerosis and Parkinson’s disease. The incidence and prevalence rates of CD and UC in Canada are reported to be among the highest in the world, and the rate of pediatric-onset IBD diagnoses continues to significantly increase. Canadian statistics align with global trends of increasing incidence and prevalence of IBD in developed and developing countries. IBD affects approximately 1.7 million Americans (estimated 780,000 with CD; estimated 907,000 with UC), with an incidence rate of 10.7 per 100,000 persons for CD and 12.2 per 100,000 persons...
with UC.\textsuperscript{4,5} The annual incidence of CD and UC in Europe was reported as 12.7 per 100,000 person-years and 24.3 per 100,000 person-years, respectively, with a reported CD prevalence of 322 per 100,000 persons and UC prevalence of 505 per 100,000 persons.\textsuperscript{3} The incidence and prevalence rates of both CD and UC in Asia reflect a rising trend, correlating with an increase in industrialization in this area of the world that historically has not experienced significant IBD.\textsuperscript{3} The financial burden of IBD is substantial, with direct medical costs in excess of CAD $1.2 billion and indirect costs approximating CAD $1.6 billion in 2012.\textsuperscript{6} Health-related quality of life scores are reproducibly decreased in patients living with IBD compared with individuals without IBD.\textsuperscript{1,7–9}

Given the significant global burden of IBD, there exists a need for safe and potent biological therapy options to effective treat individuals with moderate-to-severe phenotypes of UC and CD. There has been much speculation as to the potential role of vedolizumab (VDZ) for the treatment of UC and CD when the drug was still development.\textsuperscript{10,11} This review is intended to persuasively demonstrate that VDZ, an anti-α4β7 integrin antagonist, is an efficacious and safe alternative to tumor necrosis factor alpha (TNFα) antagonist treatment options for both UC and CD without the serious complication of progressive multifocal leukoencephalopathy (PML) previously associated with natalizumab.

**Current IBD therapy paradigm**

The goal of medical treatment in IBD is primarily focused on interrupting or modifying the aberrant immune response to induce and sustain mucosal remission so as to 1) minimize complications leading to hospitalizations and surgery; 2) modify extra-intestinal disease; and most importantly, 3) optimize quality of life.\textsuperscript{12,13}

**Mild-to-moderate UC and Crohn’s disease**

Mild-to-moderate disease is most often satisfactorily managed with oral and/or rectal therapies, such as 5-aminosalicylic acid preparations, to induce and maintain remission. Induction of remission can also be achieved with pulsed corticosteroids (CSs), such as oral prednisone or budesonide, which are tapered over a number of weeks. Immunosuppressants, such as thiopurines or methotrexate, may be required for remission maintenance in certain individuals.\textsuperscript{12}

**Moderate-to-severe UC and Crohn’s disease**

More severe disease phenotypes will often require frequent courses of CSs (steroid-dependent) or may fail to respond appropriately to steroid therapy (steroid refractory), requiring an escalation to biological therapies (with or without immunomodulators) or progression to surgery.\textsuperscript{12,13} Although there has been an observed global decrease in the surgical rate for individuals with IBD that may be attributed to increased utilization of immunsuppressant and biologic therapies, and access to specialized IBD care,\textsuperscript{6,14,15} surgery will still be required for approximately 23%–45% of individuals with UC and up to 75% of individuals with CD.\textsuperscript{16}

**Biological therapies**

**Tumor necrosis factor alpha inhibition**

The dysregulated immune response of IBD triggers activation of the innate immune system which in turn produces cytokines such as TNFα, and activation of the adaptive immune system with subsequent recruitment of pro-inflammatory T-cells and B-cells to the colon or small bowel. This consequently leads to a further amplification of pro-inflammatory cytokine release that bind to cognate receptors and activate intercellular pathways, such as JAK and STAT, to mediate tissue inflammation. Biological therapy directed toward the inhibition of anti-TNFα has been studied as a treatment modality for IBD since the early 1990s\textsuperscript{17} with the introduction of infliximab (Remicade\textsuperscript{®}; Janssen Pharmaceutical, Beerse, Belgium).\textsuperscript{18} Since then, adalimumab (Humira\textsuperscript{®}; AbbVie Corporation, North Chicago, IL, USA),\textsuperscript{19} golimumab (Simponi\textsuperscript{®}; Janssen Pharmaceutical),\textsuperscript{20} and certolizumab pegol (Cimzia; UCB Inc.; Brussels, Belgium)\textsuperscript{21} have been approved for use in UC and/or CD treatment. These immunoglobulin G1 (IgG1) monoclonal antibodies (mAbs) or Fragment AB, F(ab')\textsubscript{2} bind to and neutralize soluble and transmembrane TNFα, thereby impeding TNFα-receptor binding, disrupting the TNFα inflammatory pathway, and modifying the cellular immune response.

In CD, infliximab (ACCENT 1;\textsuperscript{22} SONIC\textsuperscript{23}) and adalimumab (CLASSIC I,\textsuperscript{24} CLASSIC II,\textsuperscript{25} CHARM\textsuperscript{26}) were shown to be efficacious in inducing and maintaining sustained clinical response and clinical remission in moderately-to-severely active disease in adults who have not achieved an adequate response with conventional therapy, as well as pediatric patients (infliximab-REACH;\textsuperscript{27} adalimumab-Study M06-806 IMAgINE\textsuperscript{28}). Additionally, infliximab demonstrated effectiveness in inducing mucosal healing and reducing corticosteroid use (ACCENT 1;\textsuperscript{22} SONIC\textsuperscript{23}), and was shown to be a successful maintenance therapy for fistulizing CD (ACCENT 2\textsuperscript{29}) in this adult population. Table 1 summarizes the pivotal anti-TNFα studies conducted in CD.

Similarly, in UC, efficacious induction and sustained maintenance of clinical response and clinical remission in adults with moderately-to-severely active disease can be achieved

1. Petkau and Eksteen

2. Dovepress

3. Biologics: Targets and Therapy downloaded from https://www.dovepress.com/ by 54.70.40.11 on 08-May-2018

For personal use only.
**Table 1** Summary of pivotal anti-TNFα studies in Crohn’s disease

<table>
<thead>
<tr>
<th>Study</th>
<th>Drug</th>
<th>Anti-TNFα Tx naïve or experienced</th>
<th>Dosing regimen</th>
<th>Key endpoint outcome(s)</th>
</tr>
</thead>
</table>
| Targan et al.  | IFX  | Naïve                             | IFX (cA2) 5 mg/kg Tx Group: 5 mg/kg IV single infusion  
IFX (cA2) 10 mg/kg Tx Group: 10 mg/kg IV single infusion  
IFX (cA2) 20 mg/kg Tx Group: 20 mg/kg IV single infusion  
PBO Group: PBO single infusion | Wk 4 clinical response (CDAI-70 response)  
IFX (cA2) 5 mg/kg Tx Group: 81% (22/27)  
IFX (cA2) 10 mg/kg Tx Group: 50% (14/28)  
IFX (cA2) 20 mg/kg Tx Group: 64% (18/28)  
PBO Group: 17% (4/24)  
Wk 4 clinical remission (CDAI <150)  
IFX Tx Group (All Doses): 33% (27/83)  
PBO Group: 4% (1/24) |
| ACCENT-1       | IFX  | Naïve                             | IFX/PBO Tx Group 1: OL IFX 5 mg/kg IV at wk 0, followed by PBO at wks 2 and 6, then q8wks through wk 54  
IFX/IFX Tx Group 2: OL IFX 5 mg/kg IV at wk 0, followed by IFX 5 mg/kg IV at wks 2 and 6, then continuing q8wks through wk 54  
IFX/IFX Tx Group 3: OL IFX 5 mg/kg IV at wk 0, followed by IFX 5 mg/kg IV at wks 2 and 6, then IFX 10 mg/kg IV q8wks through wk 54 | Wk 2 clinical response (CDAI-70 response)  
OL IFX 5 mg/kg wk 0 Tx (all participants): 58% (335/573)  
Wk 30 clinical remission (CDAI <150) in patients with clinical response at wk 2 to OL wk 0 IFX  
IFX/IFX Tx Group 2: 39% (44/113)  
IFX/IFX Tx Group 3: 45% (50/112)  
PBO Group 1: 21% (23/110)  
Median time to loss of response (ACCENT-1 criteria)  
IFX/IFX Tx Group 2: 38 wks  
IFX/IFX Tx Group 3: >54 wks  
PBO Group 1: 19 wks |
| ACCENT-2       | IFX  | Naïve                             | IFX/IFX Tx Group: OL IFX 5 mg/kg IV at wks 0, 2, and 6, then IFX 5 mg/kg IV q8wks through wk 54  
IFX/PBO Tx Group: OL IFX 5 mg/kg IV at wks 0, 2, and 6, then PBO q8wks through wk 54 | Wk 54 complete absence of draining fistulas  
IFX/IFX Tx Group: 36% (50/138)  
PBO Group 1: 19% (27/144)  
Median time to loss of response (ACCENT-2 criteria)  
IFX/IFX Tx Group: >40 wks  
PBO Group 1: 14 wks |
| REACH          | IFX  | Naïve                             | OL IFX 5 mg/kg IV at wks 0, 2, and 6, then assessed for clinical response (PCDAI response)  
↓ Randomized treatment cohort (clinical response at wk 10):  
IFX 5 mg/kg IV q8wks Tx Group: 5 mg/kg IV q8wks through wk 46  
IFX 5 mg/kg IV q12wks Tx Group: 5 mg/kg IV q12wks through wk 46  
Permitted to escalate therapy if loss of clinical response | Wk 10 clinical response (PCDAI response)  
IFX 5 mg/kg Induction: 88.4% (99/112)  
Wk 10 clinical remission (PCDAI remission)  
IFX 5 mg/kg Induction: 58.9% (66/112)  
Wk 54 clinical response (PCDAI response) in patients with clinical response at wk 10 to OL IFX 5 mg/kg induction:  
IFX 5 mg/kg q8wks Tx Group: 63.5% (33/52)  
IFX 5 mg/kg q12wks Tx Group: 33.3% (17/51)  
Wk 54 clinical remission (PCDAI remission) in patients with clinical response at wk 10 to OL IFX 5 mg/kg induction:  
IFX 5 mg/kg q8wks Tx Group: 55.8% (29/52)  
IFX 5 mg/kg q12wks Tx Group: 23.5% (12/51) |
<table>
<thead>
<tr>
<th>Study</th>
<th>Drug</th>
<th>Anti-TNFα Tx Naïve or Experienced</th>
<th>Dosing Regimen</th>
<th>Key Endpoint Outcome(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SONIC (Colombel et al&lt;sup&gt;13&lt;/sup&gt;)</td>
<td>IFX</td>
<td>Naïve</td>
<td>IFX Tx/AZA PBO Group: IFX 5 mg/kg IV at Wks 0, 2 and 6, then IFX 5 mg/kg IV q8wks through Wk 30 or 50 + AZA PBO daily</td>
<td>Week 26 CS-Free Clinical Remission (CDAI &lt; 150)</td>
</tr>
<tr>
<td>CLASSIC-I (Hanauer et al&lt;sup&gt;14&lt;/sup&gt;)</td>
<td>ADA</td>
<td>Naïve</td>
<td>ADA 160/80 Tx Group: 160 mg SC at Wk 0, 80 mg SC at Wk 2</td>
<td>ADA 160/80 Tx Group: 36% (115/327)</td>
</tr>
<tr>
<td>CLASSIC-II (Sandborn et al&lt;sup&gt;15&lt;/sup&gt;)</td>
<td>ADA</td>
<td>Responded to ADA Induction Therapy in CLASSIC-I and Wk 2, then assessed for Clinical Remission (CDAI &lt; 150)</td>
<td>OL ADA 40 mg SC at Wk 0 (Wk 4 of CLASSIC-I) and Wk 2, then PBO through Wk 56</td>
<td>Week 56 Clinical Remission (CDAI &lt; 150) – Randomized Tx Cohort: ADA 40 EOW Tx Group: 79% (15/19)</td>
</tr>
<tr>
<td>CHARM (Colombel et al&lt;sup&gt;16&lt;/sup&gt;)</td>
<td>ADA</td>
<td>Naïve and Experienced</td>
<td>ADA/ADA EOW Tx Group: OL ADA 80 mg SC at Wk 0, 40 mg SC at Wk 2, then 40 mg SC EOW through Wk 56</td>
<td>Week 26 Clinical Remission (CDAI &lt; 150)</td>
</tr>
<tr>
<td>Study</td>
<td>Drug</td>
<td>Dosing Regimen</td>
<td>Clinical Remission</td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>------</td>
<td>----------------</td>
<td>--------------------</td>
<td></td>
</tr>
</tbody>
</table>
| GAIN  | ADA  | Experienced    | ADA Tx Group: ADA 160 mg SC at Wk 0, 80 mg SC at Wk 2  
PBO Group: PBO at Wks 0 and 2 |
| M06-806| ADA  | Experienced    | OL ADA (160 mg/80 mg for body weight ≥ 40 kg or  
80 mg/40 mg for body weight < 40 kg) at  
Wks 0 and 2, then assessed for Clinical Response ↓  
Randomized Treatment Cohort (Clinical Response at Week 4):  
High Dose Tx Group ≥ 40 kg: 40 mg SC EOW through Week 48  
High Dose Tx Group < 40 kg: 20 mg SC EOW through Week 48  
Low Dose Tx Group ≥ 40 kg: 10 mg SC EOW through Week 48  
Low Dose Tx Group < 40 kg: 5 mg SC EOW through Week 48  
Permitted to escalate therapy if loss of clinical response |
| Schreiber et al | CZP | Naive and Experienced | CZP 400 Tx Group: 400 mg SC at Wks 0, 4, and 8  
CZP 200 Tx Group: 200 mg SC at Wks 0, 4, and 8  
CZP 100 Tx Group: 100 mg SC at Wks 0, 4, and 8  
PBO Tx Group: PBO at Wks 0, 4, 8 |
| PRECISE-I | CZP | Naive and Experienced | CZP Tx Group: 400 mg SC at Wks 0, 2, and 4, then q4wks through Wk 26  
PBO Tx Group: PBO at Wks 0, 2, and 4, then q4wks through Wk 26 |

*Week 4 Clinical Remission (CDAI < 150)*  
ADA Tx Group: 21% (34/159)  
PBO Group: 7% (12/166)  
*Week 4 Clinical Response (CDAI-70 Response)*  
ADA Tx Group: 52% (82/159)  
PBO Group: 34% (56/166)  
*Week 26 Clinical Remission (PCDAI Remission):*  
High Dose Tx Group: 38.7% (36/93)  
Low Dose Tx Group: 28.4% (27/95)  
Overall Clinical Remission Rate (both Tx groups): 33.5% (63/188)
### Table 1 (continued)

<table>
<thead>
<tr>
<th>Study</th>
<th>Drug</th>
<th>Anti-TNFα Tx Naïve or Experienced</th>
<th>Dosing Regimen</th>
<th>Key Endpoint Outcome(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PRECiSe-II (Schreiber et al)</td>
<td>CZP</td>
<td>Naïve and Experienced</td>
<td>OL CZP 400 mg SC at Wks 0, 2, and 4, then assessed for Clinical Response (CDAI-100 Response) at Wk 6 → Randomized Treatment Cohort (CDAI-100 Response at Wk 6): CZP Tx Group: 400 mg SC at Wks 8, 12, 16, 20, and 24 PBO Group: PBO at Wks 8, 12, 16, 20, and 24</td>
<td>Maintenance of Clinical Response (CDAI-100 Response) Through Week 26 in Patients with Clinical Response (CDAI-100 Response) at Week 6 CZP Tx Group: 63% (135/215) PBO Group: 36% (76/210) Week 26 Clinical Remission (CDAI ≤ 150) in Patients with Clinical Response (CDAI-100 Response) at Week 6 CZP Tx Group: 48% (103/215) PBO Group: 29% (61/210)</td>
</tr>
<tr>
<td>Sandborn et al</td>
<td>CZP</td>
<td>Naïve</td>
<td>CZP Tx Group: 400 mg SC at Wks 0, 2, and 4 PBO Tx Group: PBO at Wks 0, 2, 4</td>
<td>Week 6 Clinical Remission (CDAI ≤ 150) CZP Tx Group: 32% (68/215) PBO Group: 25% (53/209)</td>
</tr>
</tbody>
</table>

**Notes:** Clinical Response by Clinical Disease Activity Index (CDAI-70 Response) score defined as decrease from baseline in CDAI score by ≥70 points. Clinical Remission by Clinical Disease Activity Index (CDAI) score < 150 defined as CDAI score < 150 points. Loss of Response (ACCENT-2 Criteria) defined as CDAI score at least 175, CDAI score increase of at least 35%, and CDAI score at least 70 points more than Week-2 CDAI for at least two consecutive visits (21 days or longer). Loss of Response (ACCENT-2 Criteria) defined as recrudescence of draining fistulas, need for change in Crohn’s Disease medication, or need for additional therapy for persistent or worsening luminal disease activity, need for surgical procedure for Crohn’s Disease, or discontinuation of study medication due to perceived lack of efficacy. Clinical Response by Pediatric Crohn’s Disease Activity Index (PCDAI) score defined as decrease from baseline in PCDAI score by ≥15 points and total PCDAI score ≥30 points. Clinical Remission by Pediatric Crohn’s Disease Activity Index (PCDAI) Score defined as PCDAI score ≤10 points. Corticosteroid-Free (CF) Clinical Remission by Clinical Disease Activity Index (CDAI) Score < 150 defined as CDAI score less than 150 points in patient who has not received budesonide ≥6 mg/day or systemic corticosteroids for at least 3 weeks. Clinical Response by Clinical Disease Activity Index (CDAI-100 Response) Score defined as decrease from baseline in CDAI score by ≥100 points. Clinical Remission by Clinical Disease Activity Index (CDAI) Score ≤150 defined as CDAI score ≤150 points.

**Abbreviations:** IFX, infliximab; ADA, adalimumab; PBO, Placebo; Tx, treatment; TNFα, Tumor Necrosis Factor Alpha; GS, Corticosteroid; AZA, Azathioprine; Wk, Week; SC, Subcutaneous; IV, Intravenous; EOW, every other week; OL, Open label; CZP, certolizumab pegol.
with infliximab (ACT 1 and ACT 2⁴⁶) and adalimumab (ULTRA 1,³⁷ ULTRA 2⁴⁸), and less robustly with golimumab (PURSUIT-SC;³⁹ PURSUIT-M⁴⁰). Infliximab was also shown to be effective in inducing mucosal healing and reducing corticosteroid use (ACT 1 and ACT 2⁴⁸). Infliximab is the only TNFα inhibitor to be approved for pediatric patients with moderately-to-severely active UC, due to its effectiveness in inducing and maintaining sustained clinical response, clinical remission, and mucosal healing (Study Peds UC⁴¹). Table 2 summarizes the pivotal anti-TNFα studies conducted in UC.

Complications of TNFα inhibitors

Safety profile and adverse events

Due to the nonspecific and total body mechanism of action of TNFα inhibitors, they are associated with important safety issues. Medically significant adverse events that have been reported for the TNFα-blocking drug class in clinical trials, post-marketing registries, and pharmacovigilance systems include: serious infections (bacterial, mycobacterial, viral, parasitic, invasive fungal, and other opportunistic infections), tuberculosis (new infection or reactivation of latent infection), lymphoma (including hepatosplenic T-cell lymphoma) and other malignancies, pediatric malignancies, new or worsening congestive heart failure, hematologic abnormalities and blood dyscrasias, hepatobiliary events, hepatitis B virus reactivation, hypersensitivity reactions (including allergic reactions, anaphylactic reactions, acute infusion reactions, and serum sickness-like reactions), autoimmunity (including autoantibodies and lupus-like syndrome), and central nervous system and peripheral demyelinating disorders.¹⁸–²¹ Live vaccine administration is not recommended in patients receiving TNFα inhibitors because of the risk of clinical and disseminated infections.¹⁸–²¹

Primary and secondary loss of response

Despite the high effectiveness of anti-TNFα therapies in patients with IBD, more than one-third of patients are primary nonresponders, and another one-third develop secondary loss of response. Optimal clinical response requires the maintenance of clinically effective drug concentrations which is highly variable among IBD patients and can be influenced by numerous factors such as sex, body weight, associated treatments (immunomodulatory drugs are known to increase anti-TNFα trough levels), route of administration, serum albumin concentration, and systemic inflammation with a markedly decreased half-life in patients with severe disease.⁴³ However, the main factor that impacts anti-TNFα pharmacokinetics and efficacy over time is immunogenicity, whereby anti-drug antibodies accelerate anti-TNFα mAb clearance and shorten the drug’s half-life.⁴³ Although humanized (ie, certolizumab) and fully human mAbs (ie, adalimumab and golimumab) are logically less immunogenic when compared with chimeric ones (ie, infliximab), they can all induce anti-drug antibodies that target the murine and/or variable domains of the drug molecule. Other factors may promote immunogenicity such as genotype in a minority of patients, and drug agitation or freeze–thaw cycles that can induce immunogenic protein aggregates. Concomitant immunomodulator use has been shown to reduce the risk of anti drug antibodies.⁴⁴

Targeting of leukocyte trafficking in IBD

Until recently, targeting the pro-inflammatory cytokines TNFα and IL-12/23 (Ustekinumab)⁴⁵,⁴⁶ have been the only treatments for individuals with moderately-to-severely active CD or UC (unresponsive or inadequately responsive to CS and immunomodulators), yet a significant proportion of such patients will be refractory to these biological drug classes or eventually lose response to therapy. This has resulted in intense investigations to identify other cytokines and pathways that become activated in the dysregulated immune response of IBD. The most advanced alternative to TNFα antagonists has been therapy that targets integrins which mediate trafficking of lymphocytes to the gut. In order to understand how these novel inhibitors of lymphocyte recruitment function, it is crucial to have a basic overview of the molecules involved in gut-specific immune cell recruitment.⁴⁷

Biological basis of leukocyte trafficking in IBD

Dendritic cells (DCs), strategically positioned in the lamina propria in close proximity to small bowel enterocytes, continuously monitor the luminal microenvironment for antigens. When a potential antigen is encountered, these CD103+ DCs⁴⁸ preferentially migrate to secondary lymphoid tissues, such as mesenteric lymph nodes and Peyer’s patches, and interact with naïve T- and B-cells to imprint knowledge of the gut-derived antigen.⁴⁹ The appropriate immune response, either pro-inflammatory (for a potentially harmful antigen) or tolerance (for an auto-antigen), is thereby generated. Additionally, this interaction induces gut specificity, an important feature of regional immunity, as these newly programmed lymphocytes will be directed back to the gut where they are most likely to encounter the antigen.⁵⁰ Figure 1 demonstrates the key interactions between DCs and naïve T-cells.
<table>
<thead>
<tr>
<th>Study</th>
<th>Drug</th>
<th>Anti-TNFα Tx naïve or experienced</th>
<th>Dosing regimen</th>
<th>Key endpoint outcome(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Probert et al 42</td>
<td>IFX</td>
<td>Naïve</td>
<td>Part 1&lt;br&gt;IFX Tx Group: 5 mg/kg IV at wks 0 and 2&lt;br&gt;PBO Group: PBO at wks 0 and 2&lt;br&gt;Part 2&lt;br&gt;OL IFX treatment group (patients with ongoing active disease at wk 6): 10 mg/kg IV single dose</td>
<td>Wk 6 clinical remission (UCSS and/or Baron score)&lt;br&gt;IFX Tx Group: 39% (9/23)&lt;br&gt;PBO Group: 30% (6/20)&lt;br&gt;Wk 8 clinical remission (UCSS and/or Baron score) in patients with ongoing active disease at wk 6 (OL IFX treatment group)&lt;br&gt;Patients who received prior Tx with IFX at wks 0 and 2: 27% (3/11)&lt;br&gt;Patients who received prior Tx with PBO at wks 0 and 2: 27% (1/9)</td>
</tr>
<tr>
<td>ACT 1 (Rutgeerts et al 36)</td>
<td>IFX</td>
<td>Naïve</td>
<td>IFX 5 mg/kg Tx Group: 5 mg/kg IV at wks 0, 2, and 6, then q8wks through wk 46&lt;br&gt;IFX 10 mg/kg Tx Group: 10 mg/kg IV at wks 0, 2, and 6, then q8wks through wk 46&lt;br&gt;PBO Group: PBO at wks 0, 2, and 6, then q8wks through wk 46</td>
<td>Wk 8 clinical response (Mayo score)&lt;br&gt;IFX 5 mg/kg Tx Group: 69.4% (84/121)&lt;br&gt;IFX 10 mg/kg Tx Group: 61.5% (75/122)&lt;br&gt;PBO Group: 37.2% (45/121)&lt;br&gt;Wk 30 clinical response (Mayo score)&lt;br&gt;IFX 5 mg/kg Tx Group: 52.1% (63/121)&lt;br&gt;IFX 10 mg/kg Tx Group: 50.8% (62/122)&lt;br&gt;PBO Group: 29.8% (36/121)&lt;br&gt;Wk 54 clinical response (Mayo score)&lt;br&gt;IFX 5 mg/kg Tx Group: 45.5% (55/121)&lt;br&gt;IFX 10 mg/kg Tx Group: 44.3% (54/122)&lt;br&gt;PBO Group: 19.8% (24/121)</td>
</tr>
<tr>
<td>ACT 2 (Rutgeerts et al 36)</td>
<td>IFX</td>
<td>Naïve</td>
<td>IFX 5 mg/kg Tx Group: 5 mg/kg IV at wks 0, 2, and 6, then q8wks through wk 22&lt;br&gt;IFX 10 mg/kg Tx Group: 10 mg/kg IV at wks 0, 2, and 6, then q8wks through wk 22&lt;br&gt;PBO Group: PBO at wks 0, 2, and 6 then q8wks through wk 22</td>
<td>Wk 8 clinical response (Mayo score)&lt;br&gt;IFX 5 mg/kg Tx Group: 64.5% (78/121)&lt;br&gt;IFX 10 mg/kg Tx Group: 69.2% (83/120)&lt;br&gt;PBO Group: 29.3% (36/123)&lt;br&gt;Wk 30 clinical response (Mayo score)&lt;br&gt;IFX 5 mg/kg Tx Group: 47.1% (57/121)&lt;br&gt;IFX 10 mg/kg Tx Group: 60.0% (72/120)&lt;br&gt;PBO Group: 26.0% (32/123)</td>
</tr>
<tr>
<td>STUDY PEDS UC (Hyams et al 41)</td>
<td>IFX</td>
<td>Naïve</td>
<td>OL IFX 5 mg/kg IV at wks 0, 2, and 6, then assessed for clinical response (Mayo score)&lt;br&gt;Randomized treatment cohort (clinical response at wk 8):&lt;br&gt;IFX 5 mg/kg IV q8wks Tx Group: 5 mg/kg&lt;br&gt;IV q8wks through wk 46&lt;br&gt;IFX 5 mg/kg IV q12wks Tx Group: 5 mg/kg&lt;br&gt;IV q12wks through wk 46&lt;br&gt;Permitted to escalate therapy if loss of clinical response</td>
<td>Wk 8 clinical response (Mayo score)&lt;br&gt;OL IFX 5 mg/kg Induction: 73.3% (44/60)&lt;br&gt;Wk 54 clinical remission (PUCAI &lt; 10) in patients with clinical response at Wk 8 to OL IFX 5 mg/kg induction&lt;br&gt;IFX 5 mg/kg q8wks Tx Group: 38.1% (8/21)&lt;br&gt;IFX 5 mg/kg q12wks Tx Group: 18.2% (4/22)</td>
</tr>
</tbody>
</table>
Selective biologics for ulcerative colitis and Crohn’s disease

ULTRA-1
(Reinisch et al37)
ADA Naïve
ADA 160/80 Tx Group: 160 mg SC at wk 0, 80 mg SC at wk 2, 40 mg SC at wks 4 and 6
ADA 80/40 Tx Group: 80 mg SC at wk 0, 40 mg SC at wks 2, 4, and 6
PBO Group: PBO at wks 0, 2, 4 and 6
Wk 8 clinical remission (Mayo score)
ADA 160/80 Tx Group: 18.5% (24/130)
ADA 80/40 Tx Group: 10.0% (13/130)
PBO Group: 9.2% (12/130)

ULTRA-2
(Sandborn et al38)
ADA Naïve and experienced
ADA Tx Group: 160 mg SC at wk 0, 80 mg SC at wk 2, then 40 mg SC EOW
PBO Group: PBO at wks 0 and 2, then EOW
Wk 8 clinical remission (Mayo score)
ADA Tx Group: 16.5% (41/248)
PBO Group: 9.3% (23/246)
Wk 52-maintenance of clinical remission (Mayo score)
ADA Tx Group: 17.3% (43/248)
PBO Group: 8.5% (21/246)

PURSUIT-SC
(Sandborn et al39)
GLM Naïve
GLM 200/100 Tx Group: 200 mg SC at wk 0, 100 mg SC at wk 2
GLM 400/200 Tx Group: 400 mg SC at wk 0, 200 mg at wk 2
PBO Group: PBO at wks 0 and 2
Wk 6 clinical response (Mayo score)
GLM 200/100 Tx Group: 51.0% (129/253)
GLM 400/200 Tx Group: 54.9% (141/257)
PBO Group: 30.3% (76/251)
Wk 6 clinical remission (Mayo score)
GLM 200/100 Tx Group: 17.8% (45/253)
GLM 400/200 Tx Group: 17.9% (46/257)
PBO Group: 6.4% (16/251)
Wk 6 clinical response (Mayo score)
Wks 30 and 54 clinical remission (Mayo score)
GLM 50 Tx Group: 23.2% (35/151)
GLM 100 Tx Group: 27.8% (42/151)
PBO Group: 15.6% (24/154)

Notes: Clinical remission by Ulcerative Colitis Symptom score (UCSS) and/or Baron Score defined as UCSS ≤ 2 and/or Baron score of 0. Clinical remission by Mayo score defined as Mayo score ≤ 2 points with no individual subscore ≥ 1 point. Clinical response by Mayo score defined as decrease from baseline in Mayo score by ≥3 points and ≥30%, with absolute rectal bleeding subscore = 0 or 1 or decrease from baseline in rectal bleeding subscore ≥ 1 point.

Abbreviations: ADA, adalimumab; EOW, every other week; GLM, golimumab; IFX, infliximab; IV, intravenous; OL, open label; PBO, placebo; SC, subcutaneous; TNFα, tumor necrosis factor alpha; Tx, treatment; wk, week.
Gut-derived DCs that express CD103 (integrin alpha-E) have the capacity to convert retinol to all-trans retinoic acid, driving the process of gut specificity. The production of all-trans retinoic acid during lymphocyte priming induces the expression of the chemokine receptor CCR9 and the integrin combination of α4β7 on the surface of T- and B-lymphocytes, providing a molecular gut-specific postal code. Once these newly generated effector T-cells and IgA-producing B-cells exit the mesenteric lymphoid tissues, they enter the systemic circulatory system and are selectively recruited to gut. Circulating T- and B-lymphocytes interact with selectins (P- and E-selectins) expressed on the surface of endothelial cells that line the small venule beds within the intestinal tract. This tethering process slows down the velocity of the lymphocytes and allows them to roll along the endothelium to sample the microenvironment for potential chemokines that could trigger recruitment. CCL25, a chemokine whose expression is restricted to the gut, binds with CCR9 on the surface of the gut-homing lymphocytes, thereby activating the integrin α4β7 to bind with MAdCAM-1. These tight adhesions cause arrest of the lymphocyte on the endothelium with subsequent migration and extravasation into target tissue. Figure 2 summarizes these key molecules and drugs currently under development to target them in IBD.

Although CCR9, α4β7, CCL25, and MAdCAM-1 represent the major elements of gut specificity, other integrins and chemokines are also expressed in the gut during inflammation, including α4β1 which binds to VCAM-1 and the CXCR3 ligands, CXCR9, and CXCR10. These molecules do not contribute to tissue specificity, but rather are a feature of generalized inflammation that can be found at other sites in the body.

Pre clinical targeting of leukocyte trafficking in IBD

In IBD, inflammation and resulting tissue injury depends on the recruitment of inflammatory cells – leukocytes such as neutrophils, lymphocytes, and monocytes – to the involved intestinal mucosa from the vascular system, in response to signaling mechanisms and mediators. The result is sustained inflammation and ongoing tissue damage. Early pre-clinical experiments focused on interfering with lymphocyte homing to the gut by targeting α4 integrins. Using cotton-top tamarins (CTTs) as an ideal study model of colitis given the symptomatic, histologic, and treatment response similarities to UC in humans, Podolsky et al. reported a statistically significant reduction in acute colonic inflammation in histological samples following the administration of anti-α4 integrin mAb. This disrupted adhesion mediated by both α4β1 and α4β7 integrins on the surface of gut-homing leukocytes. In this placebo-controlled blinded trial, HP1/2 mAb 2 mg/kg (n=12 CTT) or placebo (n=12 CTT) was administered intramuscularly on days 0–7, with blinded evaluation of acute colonic activity of day 0 and day 10 colonic mucosal pinch biopsies. The mean histologic activity grade, used to quantify colonic inflammation, was significantly reduced with the HP1/2 treatment group when comparing pre-treatment and post-treatment scores (1.6±0.3 pre-treatment vs 0.2±0.1 post-treatment; P=0.005), and when the HP1/2 treatment group was compared with placebo control group for mean Δ in pre-treatment/post-treatment scores for each arm (1.4 vs 0.6;
P<0.01). This study demonstrated the potential therapeutic impact of interfering with the recruitment (“trafficking”) of circulating inflammatory cells to areas of intestinal inflammation in response to signaling mechanisms.35

**Natalizumab—first adhesion molecule antagonist in IBD**

The first biological therapy to specifically target gut-specific leukocyte trafficking and recruitment in IBD was natalizumab (Tysabri®; Biogen Canada, Mississauga, ON, Canada).36 Acting as an antagonist against the cell adhesion molecule α4β7-integrin, this humanized mAb has the ability to block both α4β1 and α4β7 integrins (which bind to VCAM-1 and MAdCAM-1, respectively), making it selective for inflammation and infection, but nonselective for the GI tract. As VCAM-1 also has a role in cell survival, its mode of action may also impact integrin-dependent survival of cells, thereby promoting cell apoptosis of leukocytes already recruited to affected tissue.37 In a double-blind placebo-controlled study of 248 patients with moderate-to-severe CD, this drug proved to be efficacious and demonstrated significantly higher clinical response rates at weeks 4, 6, 8, and 12 in patients that received two infusions of either natalizumab 3 mg/kg or natalizumab 6 mg/kg, compared with those who received placebo.38 The onset of treatment was rapid and sustained through 8 weeks. Clinical efficacy of this drug was demonstrated in a number of subsequent clinical trials for CD, as summarized in Table 3.

Because natalizumab not only targets gut-specific inflammation through α4β7/MAdCAM-1 interactions, but also impacts nonspecific inflammation through α4β1/VCAM-1 binding, the drug gained an indication for the treatment of multiple sclerosis as α4β1/VCAM-1 represents an important inflammatory pathway in the central nervous system.59 Unfortunately, the ability of this drug to interfere with the α4β1/VCAM-1-mediated inflammatory pathway also became its downfall, as it was capable of suppressing the body’s natural immunologic control of the John Cunningham virus in individuals who were infected. Reactivation of the John Cunningham virus can lead to the development of PML, a rare and fatal demyelinating disease of the brain, as was observed in a small number of individuals treated with natalizumab.60,61 Given the significant risk for PML and the poor risk–benefit ratio of this drug, natalizumab is no longer used for the treatment of CD.

**Vedolizumab—gut-specific targeting of leukocyte trafficking in IBD**

Efforts have been refined toward specifically targeting the gut-specific α4β7 integrin in order to minimize, and ideally prevent, unwanted systemic immunosuppression associated with α4β1/VCAM-1 interactions (Figure 2). Potential emerging therapies in development include selective targeting of the β7 subunit (etrolizumab; Genentech) and selective inhibition of the MAdCAM-1 (PF-00547659; Pfizer).47 VDZ (Entyvio®; Takeda Pharmaceutical Company Limited) is, however, the lead compound in this class and it has recently become commercially available for the treatment of IBD. Administered as an intravenous infusion, VDZ is a humanized anti-α4β7 integrin IgG1 mAb that binds the activated heterodimer of α4β7.42 Whereby natalizumab only recognized the α4 subunit of the α4β1 heterodimer with no specificity for the β subunit, VDZ solely recognizes the activated α4β7 heterodimeric integrin

---

**Figure 2** Drug development targeting different elements of gut-specific trafficking of immune cells in IBD.

**Note:** Vedolizumab and AMG181 targets α4β7, natalizumab targets α4, etrolizumab selectively targets β7. PF-00547659 targets MAdCAM1, GSK-1605786 (CCX-282; Traficet-EN) targets CCR9, and BTT1023 targets VAP1. Manufacturing details: Takeda: Osaka, Japan; Amgen: Thousand Oaks, CA, USA; Elan: Dublin, Ireland; Genentech: South San Francisco, CA, USA; Pfizer: New York, NY, USA; ChemoCentryx: Mountain View, CA, USA; Biotie Therapies: Turku, Finland.

**Abbreviation:** IBD, inflammatory bowel disease.
Table 3 Summary of pivotal natalizumab studies in Crohn's disease

<table>
<thead>
<tr>
<th>Study</th>
<th>Anti-TNFα Tx naïve or experienced</th>
<th>Dosing regimen</th>
<th>Key endpoint outcome(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gordon et al&lt;sup&gt;63&lt;/sup&gt;</td>
<td>Not reported</td>
<td>NTZ Tx Group: 3 mg/kg IV at wk 0</td>
<td>Mean reduction in CDAI score</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PBO Group: PBO at wk 0</td>
<td>NTZ Tx Group: 45 points</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>PBO Group: 11 points</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Wk 2 clinical remission (CDAI &lt;150)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>NTZ Tx Group: 39% (7/18)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>PBO Group: 8% (1/12)</td>
</tr>
<tr>
<td>Ghosh et al&lt;sup&gt;58&lt;/sup&gt;</td>
<td>Naïve</td>
<td>NTZ/PBO Tx Group: NTZ 3 mg/kg IV at wk 0, PBO at wk 4</td>
<td>Wk 6 clinical remission (CDAI &lt;150)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NTZ 3 mg/kg Tx Group: NTZ 3 mg/kg IV at wks 0 and 4</td>
<td>NTZ/PBO Tx Group: 29% (20/68)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NTZ 6 mg/kg Tx Group: NTZ 6 mg/kg IV at wks 0 and 4</td>
<td>NTZ 3 mg/kg Tx Group: 44% (29/66)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>NTZ 6 mg/kg Tx Group: 31% (16/51)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>PBO Group: 27% (17/63)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Wk 6 clinical response (CDAI-70 response)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>NTZ/PBO Tx Group: 59% (40/68)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>NTZ 3 mg/kg Tx Group: 71% (47/66)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>NTZ 6 mg/kg Tx Group: 57% (29/51)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>PBO Group: 38% (24/63)</td>
</tr>
<tr>
<td>eNACT-1 (Sandborn et al&lt;sup&gt;61&lt;/sup&gt;)</td>
<td>Naïve and experienced</td>
<td>NTZ Tx Group: 300 mg IV at wks 0, 4, and 8</td>
<td>Wk 10 clinical response (CDAI-70 response)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PBO Group: PBO at wks 0, 4, and 8</td>
<td>NTZ Tx Group: 56% (408/724)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>PBO Group: 49% (88/181)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Wk 10 clinical remission (CDAI &lt;150)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>NTZ Tx Group: 37% (267/724)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>PBO Group: 30% (55/181)</td>
</tr>
<tr>
<td>eNACT-2 (Sandborn et al&lt;sup&gt;61&lt;/sup&gt;)</td>
<td>Responded to NTZ induction therapy in ENACT-I</td>
<td>NTZ Tx Group: 300 mg IV q4wks through wk 56</td>
<td>Sustained clinical response (CDAI-70 response) wk 12 through wk 36</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PBO Group: PBO IV q4wks through wk 56</td>
<td>NTZ Tx Group: 61% (103/168)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>PBO Group: 28% (48/170)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Sustained clinical remission (CDAI &lt;150)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>wk 12 through wk 36</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>NTZ Tx Group: 44% (57/130)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>PBO Group: 26% (31/120)</td>
</tr>
<tr>
<td>ENCORE (Targan et al&lt;sup&gt;64&lt;/sup&gt;)</td>
<td>Naïve and experienced</td>
<td>NTZ Tx Group: 300 mg IV at wks 0, 4, and 8</td>
<td>Sustained clinical response (CDAI-70 response) wk 8 through wk 12</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PBO Group: PBO at wks 0, 4, and 8</td>
<td>NTZ Tx Group: 48% (124/259)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>PBO Group: 32% (81/250)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Sustained clinical remission (CDAI &lt;150)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>wk 8 through wk 12</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>NTZ Tx Group: 26% (68/259)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>PBO Group: 16% (40/250)</td>
</tr>
<tr>
<td>Sands et al&lt;sup&gt;65&lt;/sup&gt;</td>
<td>Experienced (concurrent IFX 5 mg/kg q8wks)</td>
<td>NTZ/IFX Tx Group: NTZ 300 mg IV at wks 0, 4, and 8+ concurrent IFX 5 mg/kg IV q8wks</td>
<td>Clinical remission (CDAI =150) at any time during study (2° endpoint)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IFX 5 mg/kg IV q8wks</td>
<td>NTZ/IFX Tx Group: 46% (24/52)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PBO/IFX Group: PBO at wks 0, 4, and 8+ concurrent IFX 5 mg/kg IV q8wks</td>
<td>PBO/IFX Group: 41% (11/27)</td>
</tr>
</tbody>
</table>

Notes: Clinical remission by Clinical Disease Activity Index (CDAI) score <150 defined as CDAI score less than 150 points. CDAI score ≥150 defined as CDAI score less than or equal to 150 points. Clinical response by CDAI (CDAI-70 response) score defined as decrease from baseline in CDAI score by ≥70 points.

Abbreviations: IFX, Infliximab; IV, intravenous; NTZ, natalizumab; PBO, placebo; TNFα, tumor necrosis factor alpha; Tx, treatment; wk, week.

and not the individual α4 or β7 subunits. This binding specificity results in gut-selective blockade of lymphocyte trafficking, thereby making it an attractive treatment option for IBD.

**Vedolizumab in UC**

The role of VDZ as an effective induction and maintenance therapy for UC was established in the GEMINI 1 study.<sup>66</sup> This Phase III integrated induction and maintenance randomized, double-blind, placebo-controlled trial enrolled patients with active UC (defined as a Mayo score of 6–12 at screening) who had failed or were intolerant to glucocorticosteroids, immunomodulators, and/or anti-TNFα therapy. The induction therapy trial included a total of 895 patients in two treatment cohorts. Cohort 1 comprised 374 patients – stratified by...
corticosteroid use/nonuse, concomitant immunomodulator use/nonuse, and prior use of TNFα antagonist – who were randomized in a 3:2 ratio to receive VDZ 300 mg or placebo at weeks 0 and 2. A total of 521 patients in cohort 2 received open-label VDZ 300 mg at weeks 0 and 2. Both cohorts underwent endoscopic disease evaluation at week 6 to assess for clinical response, defined as a decrease in an individual’s Mayo score of at least 3 points (and at least 30% from baseline), as well as a decrease in the rectal bleeding subscore of at least 1 point or an absolute rectal bleeding subscore of 0 or 1. The 121 patients from cohort 1 and 252 patients from cohort 2 who had a clinical response to VDZ at induction continued in the maintenance therapy trial for up to 52 weeks and were randomly assigned (1:1:1) to receive VDZ 300 mg q8weeks, VDZ 300 mg q4weeks, or placebo. Patients (n=373) who did not show response at week 6 to VDZ induction therapy received VDZ 300 mg q4weeks as maintenance; patients (n=149) who received placebo as induction therapy continued to received placebo for the duration of the maintenance trial.

A significantly significant 47.1% of patients from cohort 1 treated with VDZ showed a clinical response at week 6 vs 25.5% for the placebo group (P<0.001); 44.3% of patients from cohort 2 treated with open-label VDZ also showed a clinical response. Clinical remission at week 52, defined as a Mayo score ≤2 with no subscore greater than 1, was achieved in 41.8% of patients treated with VDZ 300 mg q8weeks and 44.8% of patients treated with VDZ 300 mg q4weeks compared with 15.9% of individuals switched to placebo for maintenance (P<0.001 against placebo for both VDZ regimens). The efficacy between VDZ 300 mg dosed q4weeks compared with q8weeks was not appreciably different. Commonly reported adverse events, serious infections, opportunistic infections, and enteric infections occurred in patients treated with VDZ at a frequency similar to those treated with placebo.66 Table 4 summarizes the pivotal VDZ studies conducted in UC.

Vedolizumab in CD

An identical study design framework was utilized in the GEMINI 2 study to evaluate the effectiveness of VDZ as induction and maintenance therapy in active CD. The study population was patients with moderate-to-severe CD, defined as a Clinical Disease Activity Index (CDAI) score between 220 and 450 points at screening, who had failed or were intolerant to glucocorticosteroids, immunomodulators, and/or anti-TNFα therapy. Three hundred and sixty-eight patients, stratified by corticosteroid use/nonuse, concomitant immunomodulator use/nonuse, and prior use of TNFα antagonist, were entered into cohort 1 and randomized to receive VDZ 300 mg or placebo at weeks 0 and 2 (3:2 ratio). Cohort 2 consisted of 747 patients who were infused with open-label VDZ 300 mg at weeks 0 and 2. Endoscopic evaluation was performed at week 6 to assess for clinical remission (CDAI score of ≤150 points) and CDAI-100 response (decrease in CDAI score of 100 or more points from baseline). Patients (n=461) who achieved at least a 70 point decrease in the CDAI score at week 6 (96 patients from cohort 1; 365 patients from cohort 2) were randomly assigned (1:1:1) to receive VDZ 300 mg q8weeks, VDZ 300 mg q4weeks, or placebo for up to 52 weeks within the maintenance therapy trial. Participants (n=506) who did not show response at week 6 to VDZ induction therapy received VDZ 300 mg q4weeks as maintenance and those individuals (n=168) who received placebo as induction therapy continued to received placebo for the duration of the maintenance trial.

At week 6 endoscopic evaluation, 14.5% of patients from cohort 1 induced with VDZ were in clinical remission at week 6 compared with 6.8% for the placebo group (P=0.02); although not found to be statistically different (P=0.23), 31.4% of cohort 1 patients treated with VDZ and 25.7% of patients treated with placebo achieved a CDAI-100 response at this same time point. Clinical remission was observed in 17.7% of patients from cohort 2 treated with open-label VDZ, with 34.4% having a CDAI-100 clinical response. For patients from both cohorts who responded to VDZ induction therapy, clinical remission at week 52 was confirmed in 39.0% of patients treated with VDZ 300 mg q8weeks and 36.4% of patients treated with VDZ 300 mg q4weeks compared with 21.6% of individuals switched to placebo for maintenance (P<0.001 for VDZ q8weeks vs placebo; P=0.004 for VDZ q4weeks vs placebo). The frequency of adverse events (discussed next) was higher in the VDZ treatment group compared with individuals receiving placebo.67

The GEMINI 3 study was carried out to assess the efficacy and safety of VDZ as an induction agent for moderately-to-severely active CD patients (CDAI score between 220 and 400 at baseline) with previous anti-TNFα therapy failure, defined as primary nonresponse, secondary nonresponse (loss of response), or intolerance to 1 or more TNFα antagonists. This Phase III, double-blind, placebo-controlled trial lasting 10 weeks enrolled 416 patients of which 315 (75.7%) were individuals with previous TNFα antagonist failure and 101 (24.3%) were anti-TNFα naïve. Patients were randomized in a 1:1 fashion to receive VDZ 300 mg or placebo at weeks 0, 2, and 6. In patients with prior TNFα antagonist failure, clinical remission (CDAI score ≤150 points) was not statistically significant at week
Table 4 Summary of pivotal vedolizumab studies in ulcerative colitis and Crohn’s disease

<table>
<thead>
<tr>
<th>Study</th>
<th>IBD type</th>
<th>Anti-TNFα Tx naïve or experienced</th>
<th>Dosing regimen</th>
<th>Key endpoint outcome(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Feagan et al69</td>
<td>UC</td>
<td>Naive</td>
<td>α4β7 0.15 mg/kg SC Tx Group: 0.15 mg/kg SC single dose α4β7 0.15 mg/kg IV Tx Group: 0.15 mg/kg IV single dose α4β7 0.5 mg/kg IV Tx Group: 0.5 mg/kg IV single dose α4β7 2.0 mg/kg IV Tx Group: 2.0 mg/kg IV single dose PBO Group: PBO single dose</td>
<td>Day 30 meaningful endoscopic response α4β7 0.15 SC Tx Group: 20% (1/5) α4β7 0.15 IV Tx Group: 0% (0/5) α4β7 0.5 IV Tx Group: 60% (3/5) α4β7 2.0 IV Tx Group: 20% (1/5) PBO Group: 25% (2/8)</td>
</tr>
<tr>
<td>Feagan et al70</td>
<td>UC</td>
<td>Not reported</td>
<td>MLN02 0.5 mg/kg Tx Group: 0.5 mg/kg IV on days 1 and 29 MLN02 2.0 mg/kg Tx Group: 2.0 mg/kg IV on days 1 and 29 PBO Group: PBO on days 1 and 29</td>
<td>Wk 6 clinical remission (UCCS and MBS) MLN02 0.5 mg/kg Tx Group: 33% (19/58) MLN02 2.0 mg/kg Tx Group: 32% (19/60) PBO Group: 14% (9/63) Wk 6 decrease in UCCS ≥3 points MLN02 0.5 mg/kg Tx Group: 66% (38/58) MLN02 2.0 mg/kg Tx Group: 53% (32/60) PBO Group: 33% (21/63) Wk 6 endoscopically evident remission (MBS =0) MLN02 0.5 mg/kg Tx Group: 28% (16/58) MLN02 2.0 mg/kg Tx Group: 12% (7/60) PBO Group: 8% (5/63)</td>
</tr>
<tr>
<td>Feagan et al71</td>
<td>CD</td>
<td>Experienced</td>
<td>MLN0002 2.0 mg/kg Tx Group: 2.0 mg/kg IV on days 1 and 29 MLN0002 0.5 mg/kg Tx Group: 0.5 mg/kg IV on days 1 and 29 PBO Group: PBO on days 1 and 29</td>
<td>Day 57 clinical response (CDAI-70 response) MLN0002 2.0 mg/kg Tx Group: 53% (34/65) MLN0002 0.5 mg/kg Tx Group: 49% (30/62) PBO Group: 41% (24/58) Day 57 clinical remission (CDAI &lt;150) MLN0002 2.0 mg/kg Tx Group: 37% (24/65) MLN0002 0.5 mg/kg Tx Group: 30% (19/62) PBO Group: 21% (13/63)</td>
</tr>
<tr>
<td>Parikh et al72</td>
<td>UC</td>
<td>Naïve and experienced</td>
<td>VDZ 2 mg/kg Tx Group: 2 mg/kg IV on days 1, 15, 29 and 85 VDZ 6 mg/kg Tx Group: 6 mg/kg IV on days 1, 15, 29 and 85 VDZ 10 mg/kg Tx Group: 10 mg/kg IV on days 1, 15, 29 and 85 PBO Group: PBO on days 1, 15, 29 and 85</td>
<td>Sustained clinical response (partial Mayo score) day 29 through day 253 Combined VDZ cohort: consistently ≥50% at majority of visits PBO Group: 22%–33%</td>
</tr>
<tr>
<td>GEMINI I (Feagan et al68)</td>
<td>UC</td>
<td>Naïve and experienced</td>
<td>Induction therapy trial: Cohort 1 (Randomized Tx) VDZ Tx Group: 300 mg IV at wks 0 and 2 PBO Group: PBO at wks 0 and 2 Cohort 2 (Open Label Tx) OL VDZ Tx Group: OL VDZ 300 mg at wks 0 and 2 Maintenance therapy trial: VDZ q8wks Tx Group: 300 mg IV q8wks for up to 52 wks VDZ q4wks Tx Group: 300 mg IV q4wks for up to 52 wks PBO Group: PBO for up to 52 wks</td>
<td>Wk 6 clinical response (Mayo score) Cohort 1 VDZ Tx Group: 47.1% (106/225) Cohort 2 OL VDZ Tx Group: 44.3% (231/521) PBO Group: 25.5% (38/149) Wk 6 clinical remission (Mayo score) Cohort 1 VDZ Tx Group: 16.9% (38/225) Cohort 2 OL VDZ Tx Group: 19.2% (100/521) PBO Group: 5.4% (8/149) Wk 52 clinical remission (Mayo score) VDZ q8wks Tx Group: 41.8% (51/125) VDZ q4wks Tx Group: 44.8% (51/125) PBO Group: 15.9% (20/126)</td>
</tr>
</tbody>
</table>

(Continued)
Table 4 (Continued)

<table>
<thead>
<tr>
<th>Study</th>
<th>IBD type</th>
<th>Anti-TNFα Tx naïve or experienced</th>
<th>Dosing regimen</th>
<th>Key endpoint outcome(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>GEMINI 2</td>
<td>CD</td>
<td>Naïve and experienced</td>
<td>Induction therapy trial: Cohort 1 (Randomized Tx)</td>
<td>Wk 6 clinical response (CDAI-100 response)</td>
</tr>
<tr>
<td>(Sandborn et al&lt;sup&gt;a&lt;/sup&gt;)</td>
<td></td>
<td></td>
<td>VDZ Tx Group: 300 mg IV at wks 0 and 2</td>
<td>Cohort 1 VDZ Tx Group: 31.4% (69/220)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>PBO Group: PBO at wks 0 and 2</td>
<td>Cohort 2 OL VDZ Tx Group: 34.4% (257/747)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cohort 2 (Open Label Tx) OL VDZ Tx Group: OL VDZ 300 mg at wks 0 and 2</td>
<td>PBO Group: 25.7% (38/148)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Maintenance therapy trial: VDZ q8wks Tx Group: 300 mg IV q8wks for up to 52 wks</td>
<td>Wk 6 clinical remission (CDAI ≤ 150)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>VDZ q4wks Tx Group: 300 mg IV q4wks for up to 52 wks</td>
<td>Cohort 1 VDZ Tx Group: 14.5% (32/220)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>PBO Group: PBO for up to 52 wks</td>
<td>Cohort 2 OL VDZ Tx Group: 17.7% (132/747)</td>
</tr>
<tr>
<td>GEMINI 3</td>
<td>CD</td>
<td>Experienced</td>
<td>VDZ Tx Group: VDZ 300 mg IV at wks 0, 2 and 6</td>
<td>Wk 6 clinical response (CDAI-100 response)</td>
</tr>
<tr>
<td>(Sands et al&lt;sup&gt;a&lt;/sup&gt;)</td>
<td></td>
<td></td>
<td>PBO Group: PBO at wks 0, 2, and 6</td>
<td>VDZ Tx Group: 39.2% (62/158)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PBO Group: 22.3% (35/157)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Wk 6 clinical remission (CDAI ≤ 150)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>VDZ Tx Group: 15.2% (24/158)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PBO Group: 12.1% (19/157)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Wk 10 clinical remission (CDAI ≤ 150)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>VDZ Tx Group: 26.6% (42/158)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PBO Group: 12.1% (19/157)</td>
</tr>
</tbody>
</table>

Notes: Meaningful endoscopic response defined as 2 grade improvement in Modified Baron Score (MBS) from baseline. Endoscopically evident remission defined as MBS equal to 0. Clinical remission by Ulcerative Colitis Symptom Score (UCSS) and MBS defined as UCSS of 0 or 1 AND MBS of 0 or 1 with no evidence of rectal bleeding. Clinical response by Partial Mayo Score (PMS) defined as decrease from baseline in PMS by ≥ 2 points and ≥ 25%, with absolute rectal bleeding subscore = 0 or 1 OR decrease from baseline in rectal bleeding subscore ≥ 1 point. Clinical remission by Clinical Disease Activity Index (CDAI) score < 150 defined as CDAI score less than 150 points. Clinical response by CDAI (CDAI-70 response) score defined as decrease from baseline in CDAI score by ≥ 70 points. Clinical remission by Mayo score defined as Mayo score ≤ 2 points with no individual subscore > 1 point. Clinical response by Mayo score defined as decrease from baseline in Mayo score by ≥ 3 points and ≥ 30%, with absolute rectal bleeding subscore = 0 or 1 OR decrease from baseline in rectal bleeding subscore ≥ 1 point. CDAI score ≤ 150 defined as CDAI score less than or equal to 150 points. Clinical response by CDAI (CDAI-100 response) score defined as decrease from baseline in CDAI score by ≥ 100 points.

Abbreviations: CD, Crohn’s disease; IBD, inflammatory bowel disease; IV, intravenous; MBS, Modified Baron Score; OL, open label; PBO, placebo; TNFα, tumor necrosing factor alpha; Tx, treatment; UC, ulcerative colitis; UCSS, Ulcerative Colitis Clinical Score; VDZ, vedolizumab; wk, week.

6 (15.2% of VDZ-treated patients vs 12.1% of placebo-treated patients; P=0.433), but was statistically significant at week 10 (26.6% of VDZ-treated patients vs 12.1% of placebo-treated patients; nominal P=0.001). As CDAI-100 response (≥ 100 point decrease from baseline CDAI score) was observed in 39.2% of patients receiving VDZ at week 6 compared with 22.3% of patients treated with placebo (P=0.001), the authors of the study concluded the onset of clinical remission is likely more gradual in this patient population, thereby encouraging clinicians to consider a time point beyond week 6 to evaluate patient response before manipulating concomitant medical therapies or abandoning VDZ as a therapeutic agent. Similar to safety data reported in the GEMINI 1 study,<sup>66</sup> the frequency of adverse events in this study was comparable between VDZ-treated individuals and those treated with placebo. Table 4 summarizes the pivotal VDZ studies conducted in CD.

In order to evaluate VDZ as a maintenance therapy in moderately-to-severely active CD patients with previous anti-TNFα therapy failure, an open-label VDZ extension study is presently underway with results expected in 2016. This long-term study rolls over CD patients with no unacceptable adverse events and no need for CD-related surgery during their participation in the GEMINI 3 study.<sup>68</sup>

Clinical trials data confirm VDZ to be an effective agent for the induction and maintenance of clinical remission in IBD. Entyvio<sup>®</sup> (VDZ; Takeda Pharmaceutical Company Limited, Osaka, Japan) was approved for the treatment of moderately-to-severely active UC and moderately-to-severely active CD by the US Food and Drug Administration on May 20, 2014 and the European Commission on May 27, 2014. Health Canada approved its use in moderately-to-severely active UC on January 29, 2015. VDZ can be considered for patient’s naïve to anti-TNFα agents that have failed or are intolerant to conventional therapy with glucocorticosteroids and/or immunomodulators, or that have failed TNFα antagonists. Previous exposure to a TNFα antagonist did not substantially affect the efficacy of VDZ for inducing and...
maintaining clinical response and remission in patients with UC, and statistically significant clinical response and remission was achievable in patients with CD who had previously failed or been intolerant to up to three anti-TNFα agents. This is an important clinical consideration when there is a significant proportion of individuals who are refractory or who ultimately lose response to anti-TNFα therapy.

The Toronto Consensus Statement released in May 2015 positions VDZ as a therapy to consider in the moderately-to-severely active ambulatory UC patient when symptoms persist after 2 weeks of oral corticosteroid therapy or if symptomatic response has not been achieved with anti-TNFα as monotherapy or in combination with an immunomodulator. It is anticipated that a formal consensus statement for the use of VDZ in CD will be forthcoming as clinicians integrate this drug into clinical care.

**Vedolizumab versus anti-TNFα therapy in Crohn’s disease**

As there are no direct comparative trials, it is not clear if anti-TNFα therapy as monotherapy or in combination with an immunosuppressant is equivalent or superior to VDZ for both the induction of remission and the maintenance of remission in CD. A recent network meta-analysis found VDZ to be superior only to placebo (odds ratio [OR], 2.0; 95% Credible Interval [CrI], 1.2–3.3), azathioprine/6-mercaptopurine (OR, 1.6; 95% CrI, 0.78–3.2), methotrexate (OR, 1.3; 95% CrI, 0.53–3.2), and certolizumab (OR, 1.4; 95% CrI, 0.77–2.7) for the induction of remission. When considering the maintenance of remission, VDZ was found to be superior only to placebo (OR, 2.2; 95% CrI, 1.3–3.7), azathioprine/6-mercaptopurine (OR, 1.3; 95% CrI, 0.65–2.3), and certolizumab (OR, 1.1; 95% CrI, 0.57–2.1). These data are fraught with potential biases, as the individual drugs might not necessarily be targeting the same responder who may have different biology and disease distribution. As such, proper head-to-head studies are required.

**Vedolizumab and acute, severe IBD**

Given the observed differences in the efficacy of VDZ in UC compared with CD, one must consider this gradual onset of clinical response and remission as a characteristic of lymphocyte trafficking modulators, as this delayed onset was also observed with natalizumab. We speculate there may be a necessity for a “co-inducer” such as bridging CSs when VDZ treatment is initiated, as exploratory subgroup analysis reported statistically significant increased rates of clinical remission (CDAI score ≤150 points) at week 10 both in the TNFα antagonist failure population on concomitant CSs receiving VDZ compared with the TNFα antagonist failure population on concomitant CS receiving placebo (30.2% versus 10.6%; P=0.002), and in the overall population on concomitant CSs receiving VDZ compared with the overall population on concomitant CS receiving placebo (34.5% versus 12.0%; P=0.0001). Given this gradual onset of therapeutic benefit observed in clinical trials, it is unlikely that VDZ will have a significant role in the urgent management of extremely severe or fulminant IBD.

**Vedolizumab safety**

With respect to the safety of VDZ, no cases of PML occurred across the three Phase III studies. In GEMINI 1, the frequency of commonly reported adverse events, opportunistic infections, and enteric infections in UC patients treated with VDZ was similar to placebo. In comparison, the incidence of infections, serious infections, serious adverse events, and nasopharyngitis was more frequently observed in CD patients treated with VDZ compared with placebo. Nasopharyngitis, headache, arthralgia, upper respiratory tract infection, cough, abdominal pain, fatigue, and influenza are listed as the most common side effects of the drug in the Patient Medication Information leaflet (part III of product monograph).

Clinically significant infusion reactions were uncommon, only requiring discontinuation of VDZ therapy for three individuals in GEMINI 1 and one individual in GEMINI 2 (no data reporting infusion reactions available for GEMINI 3). Immuno-genicity is uncommon, with only 3.7% of the 620 patients with blood samples suitable for drug antibody testing in GEMINI 1 having VDZ antibodies at any given time through the induction and maintenance periods, and 4.1% of patients in GEMINI 2 having detectable VDZ antibodies. Pre-medications (antihistamine, hydrocortisone, corticosteroid, and/or acetaminophen) are not standardly required or recommended, unless the patient has experienced a mild-to-moderate infusion-related reaction to VDZ. Concomitant treatment with an immunomodulator was associated with a decrease in immunogenicity and may be considered for individual patients.

**Vedolizumab and enteric pathogens**

*Clostridium difficile* and other enteric infections did not occur more frequently than placebo in clinical trials, a valid concern when considering the gut-specific mechanism of action of VDZ. Wyant et al conducted a Phase I, randomized, double-blind, placebo-controlled, parallel-group single center non-inferiority trial, whereby 127 healthy volunteers were randomized 1:1 to receive a single dose of VDZ 750 mg or placebo at day 0, followed by an accelerated immunization
dosing schedule of intramuscular hepatitis B vaccine (HBV) on days 4/32/60 and oral cholera vaccine (OCV; Dukoral®) on days 4/18. HBV seroconversion (defined as hepatitis B surface antibody titer \( \geq 10 \text{ IU/L} \)) and OCV seroconversion (defined as \( >4\text{fold increase in serum cholera toxin antibodies from baseline} \) was tested at day 74. HBV seroconversion to the parenteral hepatitis B vaccine was observed in 90.3% of individuals initially treated with placebo and 88.5% of individuals treated with VDZ, whereas OCV seroconversion to the enteral OCV was observed in 96.8% of individuals initially treated with placebo and 82.5% of individuals treated with VDZ. Further, the humoral response to OCV was markedly reduced in individuals treated with VDZ who demonstrated an OCV seroconversion, compared with individuals treated with placebo who seroconverted in response to OCV, providing further evidence of the gut selectivity of this molecule.

The study authors speculated that T-cell-dependent immune defenses are attenuated, but not completely blocked, in response to OCV with concurrent administration of VDZ. From this study and the safety outcomes reported in clinical trials, it may be concluded that VDZ does exert an effect on the lymphocyte trafficking to the gut, but does not obliterate an individual’s own immune response to enteric infections. This is an important observation as IBD patients are more prone to infections of the gut and require appropriate immune responses to control enteric microorganisms encountered in the luminal environment while limiting the inappropriate immune response characteristic of IBD.

Potential extended indications for vedolizumab

There is the potential for extended therapeutic use of VDZ beyond IBD. Primary sclerosing cholangitis (PSC) is a chronic immune-mediated cholestatic liver disease of unknown etiology that results in progressive fibrostenotic strictures of the entire biliary tree eventually leading to liver cirrhosis and end-stage liver disease. PSC stands out among other forms of liver disease owing to its close association with IBD. Between 2.5% and 7.5% of individuals with IBD will eventually develop PSC and, conversely, between 60% and 70% of patients with PSC will develop IBD. This association is discontinuous as PSC can arise many years after the initial diagnosis of IBD or, in some instances, after a curative colectomy for UC has been performed. It is also well recognized that IBD can arise de novo after a successful liver transplant for PSC, thus suggesting a very close relationship and shared pathogenesis between PSC and IBD.

In PSC, there is aberrant expression of gut-specific chemokine CCL25 on hepatic sinusoidal endothelium which binds to CCR9 on gut tropic T-cells, activating \( \alpha_4\beta_7 \) to recruit pro-inflammatory gut T-cells from the intestinal tract to the PSC liver. MAdCAM-1 and CCL25 expression, usually confined to the gut, has also been observed on liver endothelium in association with PSC, leading to increased trafficking of mucosal T-cells and chronic IBD related-liver inflammation. Therefore, VDZ may be a potential effective therapy for the treatment of PSC. To further investigate this hypothesized mechanism of chronic liver inflammation and injury, a Phase III randomized control study of VDZ in PSC is planned to commence in 2016.

Individuals with IBD often develop seronegative arthritis as an extra-intestinal manifestation of their IBD. Joint arthropathies may be the consequence of flawed mucosal leukocyte trafficking to the synovium of affected joints, as has been demonstrated in experimental models where gut derived T-cells were observed to bind to synovial tissue. The exact mechanism by which gut-homing lymphocytes bind to inflamed synovium is not well understood; earlier attempts hypothesized that \( \alpha_4\beta_7 \) lymphocytes found in inflamed synovium must partially use integrins and adhesion molecules other than MAdCAM-1 such as VAP-1 to transmigrate across the endothelium into synovial tissue, as MAdCAM-1 is lacking on the endothelium of inflamed synovial blood vessels. This necessitates further investigations, but aberrant expression of gut-adhesion molecules may be implicated in seronegative arthritis given the association of this extra-intestinal manifestation with IBD. Long-term clinical use of VDZ in the IBD population combined with controlled clinical trials specifically designed to investigate the impact of this drug on seronegative arthritis will be required to further delineate the exact molecular mechanism of joint inflammation and chronic injury.

Conclusion

In summary, VDZ has emerged as a viable and efficacious alternative to TNF\( \alpha \) antagonist treatment in both UC and CD without the serious complication of PML associated with its predecessor, natalizumab. The mechanism of action appears to be restricted to the gut without complete abrogation of the host immune system, preserving mucosal immunity that is relatively intact and capable of coping with enteric infections.

The future of anti-adhesion therapy in IBD will be focused on delineating the integrated, and often redundant, inflammatory pathways that contribute to chronic inflammation of the gut and associated extra-intestinal manifestations. Etrolizumab, PF-00547659 and CCR9 antagonists such as GSK-1605786 (formerly CCX-282; Traficet-EN, Chemo-Centryx; New York, NY, USA) have been or continue to be...
investigated, but have not yet received regulatory approval for clinical use. The next logical progression in drug development is to consider new targets, such as the αE subunit of the gut-specific αβ7 integrin, or multi-target therapy such as the collaboration between ChemoCentrxy and GSK (Brentford, Middlesex, UK) to develop a next-generation CCR9 inhibitor (CCX507) that works in combination with an αβ7 integrin antagonist to provide an amplified treatment effect that surpasses monotherapy with either agent.

Future drug development in IBD is not solely restricted to gut-specific targets, but also include intracellular messengers such as tyrosine kinases. JAK1 plays important role in signal transduction of the interleukins. Tofacitinib is a JAK inhibitor that can block this signaling pathway and is under investigation in IBD. Other approaches include anti-interleukin 12/23 antibody treatments and non-gut-selective chemokine antagonists such as anti-CXCL10 antibodies. It is likely that combinations of these therapies will emerge and companion diagnostics to personalize treatments to target in individuals with IBD.

Acknowledgment
This research was supported by the Canadian Institutes for Health Research (CIHR).

Author contributions
All authors contributed toward data analysis, drafting and revising the paper and agree to be accountable for all aspects of the work.

Disclosure
The authors report no conflicts of interest in this work.

References
Selective biologics for ulcerative colitis and Crohn's disease


54. Butter EC. Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell. 1991;67:1033–1036.


